Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Announces Earnings Results

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) issued its earnings results on Tuesday. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05, Zacks reports. The company had revenue of $5.63 billion for the quarter, compared to the consensus estimate of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.6%

Shares of NYSE FMS traded down $0.14 during midday trading on Wednesday, hitting $24.16. 530,249 shares of the stock traded hands, compared to its average volume of 361,686. The company has a market cap of $14.17 billion, a PE ratio of 19.80, a P/E/G ratio of 0.64 and a beta of 0.92. Fresenius Medical Care AG & Co. KGaA has a one year low of $20.76 and a one year high of $30.46. The business has a 50 day moving average price of $26.05 and a two-hundred day moving average price of $26.59. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.08 and a current ratio of 1.44.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 141.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,906 shares of the company’s stock worth $83,000 after purchasing an additional 1,704 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Fresenius Medical Care AG & Co. KGaA by 21.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock worth $146,000 after acquiring an additional 896 shares during the last quarter. AQR Capital Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 14.2% in the 1st quarter. AQR Capital Management LLC now owns 14,297 shares of the company’s stock worth $356,000 after acquiring an additional 1,777 shares during the last quarter. Sei Investments Co. increased its stake in Fresenius Medical Care AG & Co. KGaA by 26.9% in the 2nd quarter. Sei Investments Co. now owns 12,592 shares of the company’s stock worth $360,000 after acquiring an additional 2,670 shares during the last quarter. Finally, Osaic Holdings Inc. increased its stake in Fresenius Medical Care AG & Co. KGaA by 635.9% in the 2nd quarter. Osaic Holdings Inc. now owns 14,351 shares of the company’s stock worth $410,000 after acquiring an additional 12,401 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on FMS shares. Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 25th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Finally, Weiss Ratings upgraded Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Hold” and an average price target of $27.80.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.